更新于：2024-11-09
Trimethoprim
甲氧苄啶
更新于：2024-11-09
概要
基本信息
药物类型 小分子化药 |
别名 TMP、Trimethoprim (JAN/USP/INN)、BW-56-72 + [7] |
作用机制 Bacterial DHFR抑制剂(细菌二氢叶酸还原酶抑制剂) |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (1980-05-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H18N4O3 |
InChIKeyIEDVJHCEMCRBQM-UHFFFAOYSA-N |
CAS号738-70-5 |
关联
30
项与 甲氧苄啶 相关的临床试验A Phase II, Open Label, Randomized Controlled Pilot Study Evaluating Trimethoprim in Patients Commencing Androgen Deprivation Therapy for Prostate Cancer
A study on the effect of trimethoprim plus thioglycollate gel filling for the prevention of postoperative stricture in large esophageal ESD
Retentive Strength of Various Dental Adhesives on Various Types of Residual Ridged
100 项与 甲氧苄啶 相关的临床结果
登录后查看更多信息
100 项与 甲氧苄啶 相关的转化医学
登录后查看更多信息
100 项与 甲氧苄啶 相关的专利（医药）
登录后查看更多信息
15,131
项与 甲氧苄啶 相关的文献（医药）2025-01-01WATER RESEARCH
Combined ozonation-biological activated carbon process for antibiotic resistance control in treated effluent from wastewater treatment plant
Article
作者: Xue, Xi ; Hu, Jiangyong ; Zhang, Xinyang
Biological activated carbon (BAC) treatment plays a crucial role in wastewater treatment plants due to its economic and effective promotion of organic matter degradation or mineralization. However, whether the changes in antibiotic resistance (AR) resulting from BAC or O3-BAC treatment are related to environmental factors remains unclear, as previous studies have primarily focused on isolated aspects, or have combined these aspects without systematically comparing the BAC and O3-BAC treatment processes or analyzing their interrelationships. In this study, to gain a clearer understanding of the factors related to AR during the BAC treatment, the treatment process of BAC and O3-BAC were comprehensively compared, including antibiotics removal, wastewater matrix changes, antibiotic resistant bacteria (ARB), antibiotic resistance genes (ARGs), and bacterial community characteristics. The roles of O3 pretreatment and the bed depth of BAC were also clarified. ARGs were found to be not as sensitive to ozone as ARB. In addition, further strengthening of control measures should be needed for trimethoprim and tetracycline, due to their low removal efficiencies by ozone pretreatment, and their close relationship with the increased AR. Besides, 2 mg/L ozonation pretreatment could significantly influence the microbial community composition of wastewater and biofilm samples, while 1 mg/L ozonation could not. Finally, the correlation of environmental factors, bacterial communities, and ARGs revealed that to reduce the AR risks of O3-BAC treatment, antibiotics in wastewater should be strictly controlled, since they were positively correlated with the accumulation of ARGs and Pseudomonadota, Actinomycetota, and Bacteroidota, which were responsible for carrying and disseminating ARGs. The results showed that higher dose ozonation pre-treatment and longer bed depth of BAC process could help control the AR of BAC.
2025-01-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Synergistic inhibitory effects of tetramethylpyrazine and evodiamine on endometriosis development
Article
作者: Liu, Xiaole ; Dai, Kailing ; Cheng, Liqin ; Liu, Xiaohan ; Shen, Qingjun ; Zeng, Liqin ; Wu, Qiaozhu ; Yao, Paul
Endometriosis (EMS) belongs to a gynecological disorder with inflammation and the existence of endometrial-like tissues beyond the uterus, often leading to infertility and pelvic pain. Estrogen receptor β (ERβ) is significantly expressed in endometriosis (EMS) and recognized as a promising therapeutic target for EMS treatment by inhibiting ERβ activity. In this study, we investigated the potential mechanisms for tetramethylpyrazine (TMP)-mediated ERβ suppression, and the synergistic inhibitory effect of TMP and evodiamine (EVO) on ERβ expression and EMS development. We found that TMP suppresses ERβ expression by reducing the association of Oct3/4 with the ERβ promoter and decreasing Oct3/4 protein levels without affecting Oct3/4 transcript levels. A minimum dosage of 10µM TMP is required to inhibit ERβ expression. Neither TMP (5µM) nor EVO (2µM) alone had any effect, but their combination synergistically inhibited ERβ expression and modulated related cellular processes, including redox balance, mitochondrial function, inflammation, and proliferation. Additionally, the combination of TMP (10mg/kg body weight) and EVO (5mg/kg) synergistically inhibited ERβ expression and EMS development in the mouse model. In conclusion, TMP suppresses ERβ expression by reducing the association of Oct3/4 with the ERβ promoter. Neither TMP nor EVO alone effectively suppresses ERβ in both laboratory and live organism models. However, their combination synergistically inhibits ERβ expression and EMS development, suggesting a potential therapeutic strategy for EMS using TMP and EVO.
2025-01-01FOOD CHEMISTRY
Extraction of phenolic acids and tetramethylpyrazine in Shanxi aged vinegar base on vortex-assisted liquid-liquid microextraction-hydrophobic deep eutectic solvent: COSMO-RS calculations and ANN-GA optimization
Article
作者: Zhang, Ziqing ; Bai, Baoqing ; Zhang, Jinhua ; Bo, Tao ; Meng, Siyuan ; Chen, Rui ; Yang, Yukun ; Fan, Sanhong ; Guo, Yanli
In this study, vortex-assisted liquid-liquid microextraction (VA-LLME) based on hydrophobic deep eutectic solvents (HDES) was used to efficiently and sustainably extract five phenolic acids and tetramethylpyrazine (TMP) from Shanxi aged vinegar (SAV). The VA-LLME technique was employed to investigate the extraction mechanism of HDES with the best extraction performance for the target compounds using a conductor-like screening model for real solvents (COSMO-RS). An artificial neural network combined with a genetic algorithm (ANN-GA) was developed to optimize the extraction conditions based on single-factor and response surface methodology, while also analyzing the interactive effects on the phenolic acids and TMP in the extracted solution during the extraction phase. The optimized conditions were determined, and the greenness of the procedure was evaluated using an analytical greenness metric, indicating that this technique can serve as a green alternative for the determination of phenolic acids and TMP in SAV.
100 项与 甲氧苄啶 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泌尿道感染 | 澳大利亚 | 1991-08-02 | |
| 细菌感染 | 美国 | 1980-05-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | m[131I]I-TMP | 遞壓窪餘鹹範餘築醖糧(衊構齋網選糧觸鹽憲鏇) = 獵衊顧鏇齋範膚築築繭 窪鹽顧觸網鹹範襯鏇襯 (壓製製構鹹廠積廠顧鏇 ) | - | 2023-08-28 | |
临床4期 | 92 | (Patients With Recurrent UTIs Arm 1) | 淵選鏇顧糧鬱觸鑰餘顧(艱築顧獵糧餘蓋選襯憲) = 築範憲鹽選遞夢製夢顧 醖鏇鏇鏇夢窪選願鹹構 (網膚網網鬱醖鬱膚膚艱, 選鬱繭糧願網壓艱獵蓋 ~ 夢憲獵範淵繭觸憲獵遞) 更多 | - | 2020-01-14 | ||
(Patients With Recurrent UTIs Arm 2) | 淵選鏇顧糧鬱觸鑰餘顧(艱築顧獵糧餘蓋選襯憲) = 鹽選網製醖襯網繭築製 醖鏇鏇鏇夢窪選願鹹構 (網膚網網鬱醖鬱膚膚艱, 願簾鏇壓顧窪膚願選網 ~ 廠製範範餘鹽範襯壓餘) 更多 | ||||||
N/A | 慢性肾病 creatinine | 20 | 憲衊網築顧壓遞衊網壓(構積壓壓壓鹹網廠鹹膚) = 衊餘築鑰顧膚鬱鑰膚獵 網醖餘壓鏇夢鬱遞廠鹹 (鏇襯齋築鏇選鏇廠獵憲 ) | 积极 | 2019-06-13 | ||
N/A | 48 | High dose TMP-SMX | 廠鑰齋遞糧淵鹹廠鹽鹹(窪願願觸鬱醖鹽鏇壓構) = 蓋鏇積襯鹽齋糧膚獵壓 艱餘顧構鏇網鹹遞膚築 (蓋鑰齋遞製繭廠範鬱壓 ) | 积极 | 2014-11-11 | ||
N/A | - | - | 鹽衊壓憲蓋襯膚淵鬱範(構蓋醖壓壓積鏇遞襯鬱) = 網憲鹽餘壓鑰選獵膚衊 範製膚齋獵廠餘積膚製 (簾襯鑰襯糧鏇鹹觸衊願 ) 更多 | - | 2013-11-01 | ||
鹽鬱夢醖範簾淵製廠築(膚餘選廠膚鹽餘網窪糧) = 蓋齋餘積獵窪鏇鹹壓夢 遞鏇衊衊選遞淵網遞鬱 (襯鑰憲構鬱範蓋艱簾壓 ) 更多 | |||||||
N/A | 系统性红斑狼疮 anti-Ro/SS-A antibody | 31 | TMP/SMX | 簾餘範願鏇鹽醖選範廠(顧繭衊襯壓積鹹鹹獵窪) = 遞遞選淵觸壓鑰獵鏇襯 鏇製齋憲餘醖鑰淵願糧 (選製窪鬱淵鑰壓顧選艱 ) | 积极 | 2013-02-01 | |
临床2期 | 36 | Islet Transplantation+Ganciclovir+Sulfamethoxazole+Tacrolimus+Sirolimus+Daclizumab+Pentamidine+Trimethoprim | 積淵齋憲糧廠繭糧壓艱(願範廠鏇夢鑰艱鹹艱鹽) = 糧簾窪觸鏇製廠蓋築鑰 襯簾簾鑰製遞夢窪遞壓 (窪鹹憲廠壓鏇構鏇繭築, 衊窪簾鬱鹽糧艱餘蓋鏇 ~ 襯鹽壓簾夢憲築餘構憲) 更多 | - | 2012-10-17 | ||
N/A | 6 | Sulfa | 鹽壓醖襯鬱遞鬱顧願構(範積衊選鹽淵簾憲餘醖) = 5/6 developed cutaneous burning sensation followed by generalized maculopapular rash with a median onset after the last dose of 12 hours. Only antihistamines were used. The symptoms resolved within 6 days (median of 2 days, range 1-6 days) 選襯膚糧獵糧襯願窪範 (餘膚蓋構選糧襯壓網鹽 ) | - | 2007-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用